Clindamycin/adapalene/benzoyl peroxide
| Combination of | |
|---|---|
| Clindamycin | Lincosamide antibacterial |
| Adapalene | Retinoid |
| Benzoyl peroxide | Oxidizing agent |
| Clinical data | |
| Trade names | Cabtreo |
| AHFS/Drugs.com | Cabtreo |
| License data | |
| Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Clindamycin/adapalene/benzoyl peroxide, sold under the brand name Cabtreo, is a fixed-dose combination medication used for the treatment of acne.[1] It contains clindamycin, as the phosphate, a lincosamide antibacterial; adapalene, a synthetic retinoid; and benzoyl peroxide, an oxidizing agent.[1] It is applied to the skin.[1]
Clindamycin/adapalene/benzoyl peroxide was approved for medical use in the United States in October 2023.[1][2] It is the first triple-combination topical acne treatment approved by the US Food and Drug Administration.[2]
References
[edit]- ^ a b c d e "Cabtreo- clindamycin phosphate/benzoyl peroxide/adapalene gel". DailyMed. 27 October 2023. Archived from the original on 15 November 2023. Retrieved 15 November 2023.
- ^ a b "FDA Approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel For The Treatment Of Acne Vulgaris In Patients Twelve Years Of Age And Older". Bausch Health Companies Inc. (Press release). 20 October 2023. Archived from the original on 15 November 2023. Retrieved 15 November 2023.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |